Methotrexate Shows Promise in Pulmonary Sarcoidosis Study
A new clinical trial presented in Phoenix reveals methotrexate is a noninferior alternative to prednisone for lung function.
Updated on Oct. 31, 2026 in Asthma
Live Poll
Should medical treatments prioritize alternative medications to limit long-term steroid use for patients?
At the CHEST 2026 Annual Meeting in Phoenix, researcher Rohit Gupta presented trial results showing methotrexate is comparable to prednisone for treating pulmonary sarcoidosis. The study focused on patients with this inflammatory condition, measuring lung capacity changes over 24 weeks.
Why it matters
Identifying effective, noninferior treatments is vital for managing pulmonary sarcoidosis, where fibrosis and pulmonary hypertension often indicate poor health outcomes. These findings provide clinicians with evidence to weigh therapeutic options while minimizing reliance on traditional corticosteroids.
The PREDMETH trial involved 138 treatment-naive patients evaluated over 24 weeks. The adjusted difference in forced vital capacity was -1.17 percentage points, demonstrating the noninferiority of methotrexate compared to prednisone.
The players
Rohit Gupta
He is the lead researcher who presented findings on pulmonary sarcoidosis management at the CHEST 2026 meeting.
CHEST
This is the professional organization of chest physicians that hosts an annual meeting focused on pulmonary and critical care medicine.
The details
The trial assessed the ability of methotrexate to maintain lung function, specifically targeting percent-predicted forced vital capacity. Researchers noted that prognostic assessment for sarcoidosis currently relies on tools like the Walsh and modified Walsh models, which integrate pulmonary function tests with CT scan results.
Timeline
The CHEST 2026 Annual Meeting occurred in Phoenix from October 18-21, 2026.
The evaluation period for methotrexate noninferiority in the PREDMETH trial lasted 24 weeks.
Health Landscape
This research aligns with the standardized clinical assessment framework established by the Walsh and modified Walsh prognostic models. The study extends the utility of these models by testing new therapeutic interventions against the outcomes they are designed to track.
Patients diagnosed with pulmonary sarcoidosis may see shifts in standard treatment protocols if providers adopt methotrexate as a viable alternative to corticosteroids. This could potentially reduce the frequency or severity of side effects associated with long-term prednisone use.
The takeaway
Clinicians should prioritize regular monitoring of disease activity markers like C-reactive protein and soluble IL-2 receptors to manage sarcoidosis effectively. Future medical guidance will likely emphasize the need for dedicated multicenter trials to specifically address sarcoidosis-associated pulmonary hypertension.
Further reading
Learn more about advancements in respiratory care at our Asthma section.
Source note: This article includes information reported by Hcplive.
Live Poll
Should medical treatments prioritize alternative medications to limit long-term steroid use for patients?
